CA3104183A1 - Synthetic peptides, prodrugs, pharmaceutical compositions and uses - Google Patents

Synthetic peptides, prodrugs, pharmaceutical compositions and uses Download PDF

Info

Publication number
CA3104183A1
CA3104183A1 CA3104183A CA3104183A CA3104183A1 CA 3104183 A1 CA3104183 A1 CA 3104183A1 CA 3104183 A CA3104183 A CA 3104183A CA 3104183 A CA3104183 A CA 3104183A CA 3104183 A1 CA3104183 A1 CA 3104183A1
Authority
CA
Canada
Prior art keywords
seq
peptide
peptides
amino acid
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3104183A
Other languages
English (en)
French (fr)
Inventor
Caio Victor Machado Franca Do Nascimento
Diego Allons Rodrigues Dos Santos Da Silva
Perla Villani Borges Da Silva
Maria Elena De Lima Perez Garcia
Carolina Nunes Da Silva
Adriana Monteiro De Castro Pimenta
Marcella Nunes De Melo Braga
Paulo Gustavo Sampaio Lacativa
Iron Francisco DE PAULA JUNIOR
Gerhard Max GROSS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biozeus Desenvolvimento De Produtos Biofarmaceuticos
Original Assignee
Biozeus Desenvolvimento De Produtos Biofarmaceuticos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biozeus Desenvolvimento De Produtos Biofarmaceuticos filed Critical Biozeus Desenvolvimento De Produtos Biofarmaceuticos
Publication of CA3104183A1 publication Critical patent/CA3104183A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CA3104183A 2018-07-05 2019-07-04 Synthetic peptides, prodrugs, pharmaceutical compositions and uses Pending CA3104183A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694162P 2018-07-05 2018-07-05
US62/694,162 2018-07-05
US16/502,215 US10905738B2 (en) 2018-07-05 2019-07-03 Synthetic peptides, prodrugs, pharmaceutical compositions and uses
US16/502,215 2019-07-03
PCT/BR2019/050249 WO2020006617A1 (en) 2018-07-05 2019-07-04 Synthetic peptides, prodrugs, pharmaceutical compositions and uses

Publications (1)

Publication Number Publication Date
CA3104183A1 true CA3104183A1 (en) 2020-01-09

Family

ID=69059636

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3104183A Pending CA3104183A1 (en) 2018-07-05 2019-07-04 Synthetic peptides, prodrugs, pharmaceutical compositions and uses

Country Status (8)

Country Link
US (1) US10905738B2 (https=)
EP (1) EP3818070B1 (https=)
JP (1) JP7317956B2 (https=)
KR (1) KR20210029161A (https=)
CN (1) CN112654634B (https=)
BR (1) BR112021000105A2 (https=)
CA (1) CA3104183A1 (https=)
WO (1) WO2020006617A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026507422A (ja) * 2023-02-17 2026-03-04 バイオゼウス バイオファーマシューティカル エス.エー. 性機能障害の治療のための局所用ペプチド製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
AT387234B (de) 1987-03-05 1988-12-27 Vogelbusch Gmbh Vorrichtung zur zuechtung von dauerformen insbesondere filamentoeser mikroorganismen
US5470949A (en) 1992-12-15 1995-11-28 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for making amino acid glycosides and glycopeptides
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
US7585523B2 (en) 2002-08-27 2009-09-08 Targeted Medical Pharma Composition and method to augment and sustain neurotransmitter production
CA2560956A1 (en) 2004-03-29 2005-10-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
CN101563102B (zh) 2006-09-22 2014-12-17 德克萨斯系统大学董事会 治疗内皮功能障碍的方法
KR20090115852A (ko) 2007-01-19 2009-11-09 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
BRPI0800596A2 (pt) 2008-01-31 2009-09-22 Univ Minas Gerais método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
CN101585872A (zh) 2008-05-23 2009-11-25 成都蓉药集团四川长威制药有限公司 重组蛛毒蛋白、其制备方法和表达载体以及用于治疗ed的药物
KR20130139254A (ko) 2010-11-09 2013-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 피부 침투 및 세포 진입(space) 펩타이드 및 그의 사용방법
PT2899198T (pt) * 2012-08-20 2018-06-29 Univ Federal De Minas Gerais Ufmg Péptido sintético pntx(19), composições farmacêuticas e utilização
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2015162195A1 (en) 2014-04-23 2015-10-29 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2017068388A2 (pt) 2015-09-18 2017-04-27 Universidade Federal De Minas Gerais - Ufmg Uso do peptideo sintetico pntx-19 para tratamento de dor
KR101613302B1 (ko) 2015-12-30 2016-04-18 (주)넥스젠바이오텍 Sv82 폴리펩타이드 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물
KR101636851B1 (ko) 2016-06-03 2016-07-06 (주)넥스젠바이오텍 피부 세포 증식 효과가 증가한 열 안정성 인간 상피세포성장인자-거미독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물

Also Published As

Publication number Publication date
WO2020006617A1 (en) 2020-01-09
US20200108118A1 (en) 2020-04-09
US10905738B2 (en) 2021-02-02
CN112654634A (zh) 2021-04-13
JP2021530562A (ja) 2021-11-11
CN112654634B (zh) 2022-05-27
JP7317956B2 (ja) 2023-07-31
BR112021000105A2 (pt) 2021-03-30
KR20210029161A (ko) 2021-03-15
EP3818070A4 (en) 2022-03-16
EP3818070B1 (en) 2026-03-11
EP3818070A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
US12551535B2 (en) Peptide pharmaceuticals for insulin resistance
JP6585099B2 (ja) α−メラニン形成細胞刺激ホルモンのペプチド類似体
EP2710031B9 (en) Improved peptide pharmaceuticals for insulin resistance
US20200289653A1 (en) Improved peptide pharmaceuticals for insulin resistance
US6703381B1 (en) Methods for delivery therapeutic compounds across the blood-brain barrier
ES2766755T3 (es) Análogos de compstatina con propiedades farmacocinéticas mejoradas
KR102542164B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 약제
JP4147329B2 (ja) 液体形態の改良された安定性を有するコルチコトロピン放出因子の医薬製剤
US20100004165A1 (en) Novel Protein Transduction Domains and Uses Therefor
US10905738B2 (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
DE60133654D1 (de) Arzneimittel enthaltend analgetische peptide
HK40043121B (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
HK40043121A (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
CN101257927A (zh) 用于经口递送亲水性肽镇痛药的肽缀合物
TW202026305A (zh) 芋螺毒素(conotoxin)肽類似物及用於疼痛及發炎病症之治療的用途
JP2019081772A (ja) ペプチド及び関連化合物の経皮送達システム
NZ617824B2 (en) Improved peptide pharmaceuticals for insulin resistance

Legal Events

Date Code Title Description
P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240701

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241028

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241204

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241204

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250415

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625